TriaGen Wealth Management LLC Sells 310 Shares of Danaher Co. (NYSE:DHR)

TriaGen Wealth Management LLC reduced its position in shares of Danaher Co. (NYSE:DHR) by 2.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,726 shares of the conglomerate’s stock after selling 310 shares during the period. Danaher comprises about 1.0% of TriaGen Wealth Management LLC’s investment portfolio, making the stock its 20th biggest position. TriaGen Wealth Management LLC’s holdings in Danaher were worth $2,921,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in DHR. Decker Retirement Planning Inc. bought a new position in Danaher during the 4th quarter valued at about $31,000. Teachers Insurance & Annuity Association of America bought a new position in Danaher during the 3rd quarter valued at about $39,000. MidAtlantic Capital Management Inc. acquired a new stake in Danaher in the 3rd quarter valued at about $40,000. FSA Wealth Management LLC acquired a new stake in Danaher in the 3rd quarter valued at about $50,000. Finally, Darwin Wealth Management LLC acquired a new stake in Danaher in the 3rd quarter valued at about $55,000. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

NYSE:DHR opened at $222.56 on Friday. Danaher Co. has a one year low of $221.34 and a one year high of $281.70. The company has a market cap of $160.75 billion, a P/E ratio of 42.15, a P/E/G ratio of 4.22 and a beta of 0.83. The firm’s fifty day moving average price is $235.66 and its two-hundred day moving average price is $253.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.72%. During the same period in the prior year, the firm earned $2.09 EPS. Equities analysts expect that Danaher Co. will post 8.15 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were paid a $0.27 dividend. The ex-dividend date was Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.49%. Danaher’s dividend payout ratio (DPR) is presently 20.45%.

Insider Activity at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 11.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

DHR has been the subject of several research reports. Jefferies Financial Group lowered their price objective on shares of Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research report on Wednesday. Stephens reiterated an “overweight” rating and set a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. lowered their price target on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating for the company in a research report on Tuesday. Royal Bank of Canada restated an “outperform” rating and set a $277.00 price objective (down previously from $299.00) on shares of Danaher in a report on Thursday. Finally, Citigroup decreased their price objective on shares of Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a report on Thursday. Six analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average price target of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.